{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:10:03Z","timestamp":1777504203659,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010221","name":"Higher Education Commision, Pakistan","doi-asserted-by":"publisher","award":["21\u20131826\/SRGP\/R&D\/HEC\/2018"],"award-info":[{"award-number":["21\u20131826\/SRGP\/R&D\/HEC\/2018"]}],"id":[{"id":"10.13039\/501100010221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12958-4","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T09:01:36Z","timestamp":1727514096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of imidazole derivatives on cellular proliferation and apoptosis in myeloid leukemia"],"prefix":"10.1186","volume":"24","author":[{"given":"Bazla Binte","family":"Nadeem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysha","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mudassir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gul Rukh","family":"Sajjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fazal","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaheer","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilawar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"issue":"11","key":"12958_CR1","doi-asserted-by":"publisher","first-page":"992","DOI":"10.18632\/oncotarget.27513","volume":"11","author":"JJ Jimenez","year":"2020","unstructured":"Jimenez JJ, Chale RS, Abad AC, Schally AV. Acute promyelocytic leukemia (APL): a review of the literature. Oncotarget. 2020;11(11):992.","journal-title":"Oncotarget"},{"issue":"1","key":"12958_CR2","first-page":"391","volume":"2008","author":"MS Tallman","year":"2008","unstructured":"Tallman MS, Altman JK. Curative strategies in acute promyelocytic leukemia. ASH Educ Program Book. 2008;2008(1):391\u20139.","journal-title":"ASH Educ Program Book"},{"key":"12958_CR3","doi-asserted-by":"publisher","first-page":"592996","DOI":"10.3389\/fonc.2020.592996","volume":"10","author":"HH Zhu","year":"2020","unstructured":"Zhu HH. The history of the chemo-free model in the treatment of acute promyelocytic leukemia. Front Oncol. 2020;10:592996.","journal-title":"Front Oncol"},{"issue":"13","key":"12958_CR4","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1080\/10428194.2019.1613540","volume":"60","author":"M Stahl","year":"2019","unstructured":"Stahl M, Tallman MS. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leuk Lymphoma. 2019;60(13):3107\u201315.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"12958_CR5","first-page":"1172","volume":"92","author":"W Ding","year":"1998","unstructured":"Ding W, Li YP, Nobile LM, Grills G, Carrera I, Paietta E, Tallman MS, Wiernik PH, Gallagher RE. Leukemic Cellular Retinoic Acid resistance and missense mutations in the PML-RAR Fusion Gene after Relapse of Acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood. J Am Soc Hematol. 1998;92(4):1172\u201383.","journal-title":"J Am Soc Hematol"},{"issue":"6","key":"12958_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","volume":"11","author":"M Yilmaz","year":"2021","unstructured":"Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood cancer J. 2021;11(6):123.","journal-title":"Blood cancer J"},{"key":"12958_CR7","unstructured":"Acar K, Uz B. A chronic myeloid leukemia case with a variant translocation t (11; 22)(q23; q11. 2): masked Philadelphia or simple variant translocation? Pan Afr Med J. 2018;30."},{"issue":"7","key":"12958_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/sj.leu.2403797","volume":"19","author":"SD Turner","year":"2005","unstructured":"Turner SD, Alexander DR. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia. 2005;19(7):1128\u201334.","journal-title":"Leukemia"},{"issue":"8","key":"12958_CR9","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","volume":"21","author":"MW Deininger","year":"2003","unstructured":"Deininger MW, O\u2019brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637\u201347.","journal-title":"J Clin Oncol"},{"key":"12958_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.exphem.2020.09.186","volume":"90","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y, Fukushima T, Mikami K, Adachi K, Fukuyama T, Goyama S, Kitamura T. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells. Exp Hematol. 2020;90:46\u201351.","journal-title":"Exp Hematol"},{"issue":"4","key":"12958_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","volume":"10","author":"FH Heidel","year":"2012","unstructured":"Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, et al. Genetic and pharmacologic inhibition of \u03b2-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 2012;10(4):412\u201324.","journal-title":"Cell Stem Cell"},{"issue":"5973","key":"12958_CR12","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1186624","volume":"327","author":"Y Wang","year":"2010","unstructured":"Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, et al. The Wnt\/\u03b2-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327(5973):1650\u20133.","journal-title":"Science"},{"issue":"5","key":"12958_CR13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21(5):926\u201335.","journal-title":"Leukemia"},{"issue":"9","key":"12958_CR14","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1039\/C7MD00067G","volume":"8","author":"I Ali","year":"2017","unstructured":"Ali I, Lone MN, Aboul-Enein HY. Imidazoles as potential anticancer agents. MedChemComm. 2017;8(9):1742\u201373.","journal-title":"MedChemComm"},{"issue":"9","key":"12958_CR15","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/leu.2009.69","volume":"23","author":"AA Mian","year":"2009","unstructured":"Mian AA, Sch\u00fcll M, Zhao Z, Oancea C, Hundertmark A, Beissert T, et al. The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR\/ABL. Leukemia. 2009;23(9):1614\u201321.","journal-title":"Leukemia"},{"issue":"1","key":"12958_CR16","first-page":"25","volume":"5","author":"YR Saadat","year":"2015","unstructured":"Saadat YR, Saeidi N, Vahed SZ, Barzegari A, Barar J. An update to DNA ladder assay for apoptosis detection. BioImpacts: BI. 2015;5(1):25.","journal-title":"BioImpacts: BI"},{"issue":"11","key":"12958_CR17","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1039\/C4MD00277F","volume":"5","author":"GV Sharma","year":"2014","unstructured":"Sharma GV, Ramesh A, Singh A, Srikanth G, Jayaram V, Duscharla D, Jun JH, Ummanni R, Malhotra SV. Imidazole derivatives show anticancer potential by inducing apoptosis and cellular senescence. MedChemComm. 2014;5(11):1751\u201360.","journal-title":"MedChemComm"},{"issue":"28","key":"12958_CR18","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.2174\/1568026621666210527103225","volume":"21","author":"F Hu","year":"2021","unstructured":"Hu F, Zhang L, Nandakumar KS, Cheng K. Imidazole scaffold based compounds in the development of therapeutic drugs. Curr Top Med Chem. 2021;21(28):2514\u201328.","journal-title":"Curr Top Med Chem"},{"key":"12958_CR19","doi-asserted-by":"publisher","first-page":"114565","DOI":"10.1016\/j.ejmech.2022.114565","volume":"240","author":"DL Yang","year":"2022","unstructured":"Yang DL, Zhang YJ, Lei J, Li SQ, He LJ, Tang DY, Xu C, Zhang LT, Wen J, Lin HK, Li HY. Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer. Eur J Med Chem. 2022;240:114565.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"12958_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08450-y","volume":"21","author":"M Fatima","year":"2021","unstructured":"Fatima M, Kakar SJ, Adnan F, Khan K, Mian AA, Khan D. AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia. BMC Cancer. 2021;21(1):1\u20139.","journal-title":"BMC Cancer"},{"issue":"1","key":"12958_CR21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41467-018-03371-0","volume":"9","author":"Y Wu","year":"2018","unstructured":"Wu Y, Zeng J, Zhang F, Zhu Z, Qi T, Zheng Z, et al. Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. Nat Commun. 2018;9(1):918.","journal-title":"Nat Commun"},{"issue":"16","key":"12958_CR22","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1016\/j.bmc.2009.07.028","volume":"17","author":"P Zhan","year":"2009","unstructured":"Zhan P, Liu X, Zhu J, Fang Z, Li Z, Pannecouque C, De Clercq E. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem. 2009;17(16):5775\u201381.","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"12958_CR23","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.2174\/13895575113136660091","volume":"13","author":"N Rani","year":"2013","unstructured":"Rani N, Sharma A, Singh R. Imidazoles as promising scaffolds for antibacterial activity: a review. Mini Rev Med Chem. 2013;13(12):1812\u201335.","journal-title":"Mini Rev Med Chem"},{"key":"12958_CR24","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1007\/s00044-012-9972-6","volume":"21","author":"R Mishra","year":"2012","unstructured":"Mishra R, Ganguly S. Imidazole as an anti-epileptic: an overview. Med Chem Res. 2012;21:3929\u201339.","journal-title":"Med Chem Res"},{"issue":"11","key":"12958_CR25","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2174\/13895575113139990069","volume":"13","author":"N Rani","year":"2013","unstructured":"Rani N, Sharma A, Kumar Gupta G, Singh R. Imidazoles as potential antifungal agents: a review. Mini Rev Med Chem. 2013;13(11):1626\u201355.","journal-title":"Mini Rev Med Chem"},{"issue":"14","key":"12958_CR26","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.3390\/molecules26144213","volume":"26","author":"P Sharma","year":"2021","unstructured":"Sharma P, LaRosa C, Antwi J, Govindarajan R, Werbovetz KA. Imidazoles as potential anticancer agents: an update on recent studies. Molecules. 2021;26(14):4213.","journal-title":"Molecules"},{"issue":"1","key":"12958_CR27","first-page":"150845","volume":"2014","author":"M Hassan","year":"2014","unstructured":"Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. [Retracted] apoptosis and Molecular Targeting Therapy in Cancer. Biomed Res Int. 2014;2014(1):150845.","journal-title":"Biomed Res Int"},{"issue":"1","key":"12958_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1128\/AAC.01800-13","volume":"58","author":"BN Sharma","year":"2014","unstructured":"Sharma BN, Marschall M, Henriksen S, Rinaldo CH. Antiviral effects of artesunate on polyomavirus BK replication in primary human kidney cells. Antimicrob Agents Chemother. 2014;58(1):279\u201389.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"12958_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41401-020-0491-6","volume":"42","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li ZX, Zhao WC, Huang HB, Wang JQ, Zhang H, Lu JY, Wang RN, Li W, Cheng Z, Xu WL. Identification and characterization of isocitrate dehydrogenase 1 (IDH1) as a functional target of marine natural product grincamycin B. Acta Pharmacol Sin. 2021;42(5):801\u201313.","journal-title":"Acta Pharmacol Sin"},{"key":"12958_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.omtn.2017.06.023","volume":"9","author":"P Kanlikilicer","year":"2017","unstructured":"Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GL. Therapeutic targeting of AXL receptor tyrosine kinase inhibits tumor growth and intraperitoneal metastasis in ovarian cancer models. Mol Therapy-Nucleic Acids. 2017;9:251\u201362.","journal-title":"Mol Therapy-Nucleic Acids"},{"issue":"19","key":"12958_CR31","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.3390\/cancers13194864","volume":"13","author":"A Auyez","year":"2021","unstructured":"Auyez A, Sayan AE, Kriajevska M, Tulchinsky E. AXL receptor in cancer metastasis and drug resistance: when normal functions go askew. Cancers. 2021;13(19):4864.","journal-title":"Cancers"},{"issue":"3","key":"12958_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","volume":"127","author":"H Clevers","year":"2006","unstructured":"Clevers H. Wnt\/\u03b2-catenin signaling in development and disease. Cell. 2006;127(3):469\u201380.","journal-title":"Cell"},{"issue":"5","key":"12958_CR33","doi-asserted-by":"publisher","first-page":"a008052","DOI":"10.1101\/cshperspect.a008052","volume":"4","author":"P Polakis","year":"2012","unstructured":"Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4(5):a008052.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"12958_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc3419","volume":"13","author":"JN Anastas","year":"2013","unstructured":"Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13(1):11\u201326.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"12958_CR35","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41467-018-03327-4","volume":"9","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, Rudra P, Ghosh D, Zhao R, Ford HL. Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nat Commun. 2018;9(1):1047.","journal-title":"Nat Commun"},{"issue":"2","key":"12958_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/ncb1534","volume":"9","author":"A Kaidi","year":"2007","unstructured":"Kaidi A, Williams AC, Paraskeva C. Interaction between \u03b2-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol. 2007;9(2):210\u20137.","journal-title":"Nat Cell Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12958-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T09:04:35Z","timestamp":1727514275000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12958-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12958"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12958-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Protein sequences"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"DNA and RNA sequences"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"DNA and RNA sequencing data"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Genetic polymorphisms"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Linked genotype and phenotype data"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Macromolecular structure"}},{"value":"Not applicable.","order":11,"name":"Ethics","group":{"name":"EthicsHeading","label":"Microarray data (must be MIAME compliant)"}},{"value":"Not applicable.","order":12,"name":"Ethics","group":{"name":"EthicsHeading","label":"Crystallographic data for small molecules"}}],"article-number":"1200"}}